Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Assessing Patients Starting or Switching a DMARD

Arthritis Care Res; ePub 2018 Jun 8; Wohlfahrt, et al

A recent study provides support for the utility of Patient Reported Outcomes Measurement Information System (PROMIS) measures for the assessment of physical and mental health in individuals with active rheumatoid arthritis (RA). Furthermore, all PROMIS measures improved significantly after disease-modifying antirheumatic drug (DMARD) initiation, with the magnitudes of association between changes in PROMIS measures and changes in Clinical Disease Activity Index (CDAI) in the low to moderate range. Participants in an ongoing prospective observational study completed 8 PROMIS measures before and after DMARD initiation. Researchers found:

  • Among the 156 participants who completed the first study visit, the mean baseline CDAI was 25.5 ± 14.0.
  • Baseline scores for PROMIS measures of physical health, pain, and sleep were associated with baseline CDAI.
  • Among the 106 participants with 12‐week data, all PROMIS scores improved after DMARD initiation.
  • With the exception of depression, changes in all assessed PROMIS measures were correlated with changes in CDAI (standardized beta's from |0.23 ‐ 0.38|).


Wohlfahrt A, Bingham III CO, Marder W, et al. Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS) measures in RA patients starting or switching a DMARD. [Published online ahead of print June 8, 2018]. Arthritis Care Res. doi:10.1002/acr.23617.